Patent no loss of MatrixView
Tuesday, 19 August, 2008
MatrixView [ASX: MVU] has been awarded a European Patent for its proprietary ABO technology.
The patent has been awarded for the company's proprietary Advanced Binary Optimisation (ABO) technology, which allows MatrixView's healthcare products to provide lossless data streams.
ABO is the backbone of MatrixView's healthcare products - such as its tele-radiology solution - where high-resolution, highly accurate data streams are required.
Its key feature is an ability to provide mathematically lossless data management – the ability to compress large amounts of data without losing any of that data, critical in medical applications.
The company has also applied for patents for ABO from the US.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
